Canakinumab Treatment Effective for Familial Mediterranean Fever

Canakinumab may be a useful first-line treatment for renal transplant recipients with familial Mediterranean fever (FMF), according to recent research. Immunosuppressive drugs can interact with colchicine, the standard first-line treatment for FMF, and increase the incidence of side effects, such as diarrhea and myopathy...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions canakinumab Familial Mediterranean fever kidney transplant Renal transplantation Source Type: research